Tentarix Biotherapeutics Inc. is a San Diego-based biotechnology company that specializes in the development of multifunctional biologics. Their innovative approach involves selectively targeting cell types that drive therapeutic benefit, while minimizing the impact on other cells that may limit these benefits. By harnessing powerful biology and directing it to specific cell types, Tentarix aims to unlock the potential of these biologics for effective treatments. Their manufacturing process is based on robust, industrialized development, utilizing fully human antibody components to recapitulate powerful biology.
Under the leadership of Donald Santel as Interim CEO and Board Chairman, Tentarix is committed to advancing their platform programs and bringing their multifunctional biologics to market. With Stephen Demarest as Chief Scientific Officer, who has extensive experience in antibody and multi-specific protein development, and Margaret Karow as Chief Development Officer, who brings over 25 years of expertise in protein engineering, Tentarix is well-positioned to drive innovation in the field of biotechnology.
Generated from the website